ArticleCancer cell international2026
Exploring the anti-cancer potential of gut microbiota-derived short-chain fatty acids in ovarian cancer: a comparative analysis of sodium butyrate and sodium propionate on proliferation, cell cycle, and apoptosis.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundShort-chain fatty acids (SCFAs) are microbial metabolites produced by the gut microbiome through the fermentation of dietary fibers and non-digestible carbohydrates. SCFAs have received considerable interest as potential regulators of various cancers, including colorectal cancer and breast cancer. However, their roles and underlying mechanisms in ovarian cancer remain elusive. This study aimed to investigate and compare the anti-cancer effects of sodium butyrate (NaB) and sodium propionate (NaP) in two distinct ovarian cancer cell lines, SKOV-3 and PA-1.
resultsBoth NaB and NaP significantly reduced proliferation and colony formation, and impaired spheroid formation of SKOV-3 and PA-1 cells in a dose- and time-dependent manner. Notably, NaB exhibited greater anti-cancer potency than NaP, as evidenced by its lower IC₅₀ values—being 4.8-fold and 3.2-fold lower at 72 h and 96 h, respectively, in SKOV-3 cells, and 4.4-fold and 1.7-fold lower at 72 h and 96 h, respectively, in PA-1 cells. Additionally, treatment with NaB for 24 h and with NaP for 24–48 h induced cell cycle arrest at the G2/M phase in both cell lines, accompanied by an upregulation of p21 and a decrease in the expression of cyclins A2, B1, and B2. Moreover, 48 h post-treatment, both compounds induced apoptosis, with NaB demonstrating more pronounced effects. NaB increased the percentage of late apoptotic cells to 21.85% at 10 mM in SKOV-3 cells and to 69.9% at 5 mM in PA-1 cells, while 15 mM NaP resulted in 4.3% and 16.8% late apoptotic cells in SKOV-3 and PA-1, respectively. This was accompanied by modulation of apoptosis-regulatory proteins, including PARP-1 cleavage and an increased BAX/BCL2 ratio in the treated cells, suggesting the involvement of the intrinsic apoptotic pathway.
conclusionOur study demonstrated that NaB and NaP inhibited the growth and survival of two different ovarian cancer subtypes through cell cycle arrest and apoptosis. While NaB exhibited greater potency, our findings highlight the promising therapeutic potential of both compounds in ovarian cancer and lay the groundwork for further mechanistic and clinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.